Clinical trials: Alzheimer's Disease, Early Onset
Alzheimer Disease, Early Onset
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
- Trial name
- NCT06750432
- Testing
- PMN310
- Where
- 22 sites in United States
- Volunteers
- 144 people
- Sponsor
- ProMis Neurosciences, Inc
Alzheimer Disease, Early-Onset
Examining Neuroinflammation in AlzHeimer's
Alzheimer disease (AD) is a neurodegenerative disorder with a poorly understood pathology. It is an irreversible progressive brain disease that slowly deteriorates memory, thinking and behavior.
- Trial name
- ENHANCE (NCT03548883)
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AdventHealth
Alzheimers Disease, Dementia
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU-002 (NCT06647498)
- Testing
- Remternetug
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients
Neurodegenerative diseases such as Mild Cognitive Impairment, Alzheimer's, and dementia affect millions of Americans. Although these diseases are heavily researched, there is very little research examining the impact of…
- Trial name
- NCT03514875
- Testing
- MitoQ
- Sponsor
- University of Nebraska
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Down Syndrome, Cognitive Decline
GnRH Therapy on Cognition in Down Syndrome
Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old.
- Conditions
- Down Syndrome, Cognitive Decline, Alzheimer Disease, Early Onset, Olfaction Disorders
- Trial name
- NCT04390646
- Testing
- GnRH, gonadorelin acetate, 0.9% NaCl
- Where
- Switzerland
- Volunteers
- 56 people
- Sponsor
- Nelly Pitteloud
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease, Early Onset
Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease
multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate the safety and tolerability, efficacy, and PK of 60 mg AD-35 administered QD during 6 months of double-blind treatment followed by a…
- Trial name
- ROAD (NCT03625401)
- Testing
- AD-35 60mg group
- Where
- 10 sites in United States
- Volunteers
- 55 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT01760005)
- Testing
- Gantenerumab, Solanezumab, E2814
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Early Onset
The Ketogenic Diet for Alzheimer's Disease
The ketogenic diet (KD) is a metabolic shift, which stimulates the liver oxidation of fatty acids to produce ketone bodies. These ketone bodies represent an alternative fuel source for the brain.
- Trial name
- CETOMA (NCT04701957)
- Testing
- Ketogenic diet
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Early Onset Alzheimer Disease
48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease
Researchers are trying to determine the frequency of seizures and epilepsy in patients with Early-onset Alzheimer's disease (EOAD) using a 48-hour computer assisted ambulatory electroencephalogram.
- Trial name
- NCT04002583
- Testing
- Computer assisted ambulatory electroencephalogram
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Delirium, Cognitive Impairment
Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study
Cognitive skills are essential to live independently, manage finances, maintain employment, and function in society. Loss of these cognitive skills puts a tremendous burden on society as seen with dementias, Alzheimer's disease…
- Conditions
- Delirium, Cognitive Impairment, Alzheimer; Early Onset, Trauma
- Trial name
- INSIGHT-ICU (NCT03098459)
- Testing
- Non-interventional observational prospective cohort study
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Vanderbilt University Medical Center
Alzheimer Disease, Early Onset
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants…
- Trial name
- NCT07328451
- Testing
- DNL628
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Denali Therapeutics Inc.
Alzheimer Disease, Early Onset
The Resting-state EEG Gamma Oscillations in Alzheimer's Disease
The literature suggests a strong association between amyloid accumulation and gamma alterations, emerging gamma activity as a biomarker candidate for Alzheimer's pathology.
- Trial name
- EEG (NCT05989087)
- Testing
- CSF
- Where
- Turkey (Türkiye)
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Görsev Yener, MD, PhD
Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease
Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease
Alzheimer's disease (AD) is the leading neurodegenerative disease of aging characterized by multiple cognitive impairments. Given the recent failures of disease-modifying drugs, the current focus is on preventing or mitigating…
- Conditions
- Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease, Logopenic Progressive Aphasia
- Trial name
- NCT04122001
- Testing
- Active, in-person HD-tDCS or active remote tDCS, Word List Learning Intervention (WordLLI)
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Engagement 2.0 Forms of Consent for Data (re-)Use
The objective of this qualitative study is to create a better understanding of patients' mental model of health data engagement interfaces and tools (such as Dynamic Consent).
- Trial name
- ENGAGE (NCT05229978)
- Testing
- Showing an existing Dynamic Consent (computer interface) as prompt
- Where
- Belgium
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Alzheimer Disease, Alzheimer Disease, Early Onset
Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease
New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies.
- Trial name
- TMSLA (NCT07036328)
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Netherlands
- Volunteers
- 55 people
- Sponsor
- Willem de Haan
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT06424236)
- Testing
- Gantenerumab
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Early Onset
Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study
The purpose of this study is to generate preliminary data on the benefit of computerized cognitive training and Tai Chi- Qi Gong training in participants with Early-Onset Alzheimer's Disease.
- Trial name
- LITES (NCT05573490)
- Testing
- Cognitive Training, Tai Chi- Qi Gong, Brain Games
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Indiana University
Alzheimer Disease, Early Onset
Efavirenz for Patients With Alzheimer's Disease
This will be a two-center, placebo controlled blinded clinical trial to evaluate the safety and tolerability of efavirenz (EFV) in 36 clinically stable subjects with mild cognitive impairment/early dementia due to Alzheimer's…
- Trial name
- EPAD (NCT03706885)
- Testing
- Sustiva Pill
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Western Reserve University